Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UPEC-FimON
- Development stage
- Phase 1
- Lead developer
- Hopec Pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravesical
01
Overview
UPEC-FimON (also known as DOR-100 or HOPEC) is a first-in-class, whole-cell, inactivated, genetically modified bacterial immunotherapy developed by Hopec Pharma for the treatment of non-muscle invasive bladder cancer (NMIBC). It consists of a genetically engineered strain of uropathogenic Escherichia coli (UPEC) that lacks hemolysin A and is modified to constantly express type 1 fimbriae. The fimbriae allow the bacteria to selectively bind to mannosylated (mannose-rich) receptors, which are overexpressed on bladder cancer cells. Following attachment, the bacteria trigger a localized immune response mediated by T cells and natural killer (NK) cells against the tumor. The bacteria are inactivated with formaldehyde to preserve their binding capability while eliminating the risk of infection. UPEC-FimON is administered intravesically and is being evaluated in Phase Ia/Ib clinical trials as an alternative to Bacillus Calmette-Guérin (BCG) and standard intravesical chemotherapies.
- Brand names
- HOPEC
- Other names
- Inactivated UPEC-FimONInactivated Uropathogenic E. coli (UPEC-FimON)
02
Targets
FimH (Type 1 fimbrial adhesin)
Beyond the preview
Go deeper on UPEC-FimON.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UPEC-FimON.